The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Optimizing maintenance strategies in multiple myeloma
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses findings from an EMN network meta-analysis evaluating maintenance strategies in multiple myeloma. He highlights evidence supporting combination maintenance, particularly daratumumab plus lenalidomide and carfilzomib-based regimens, over lenalidomide alone, with treatment intensity and duration potentially guided by disease risk and measurable residual disease status. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
